FABP4 and gastrointestinal stromal tumor: After three kinds of GIST cells were treated with imatinib, the following figure showed that the expression of FABP4, COL4A1, and RGS4 in imatinib-sensitive lines GIST882 and GIST-T1 decreased significantly compared with GIST430 cell lines.